http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Nobuhisa Kanahara(Nobuhisa Kanahara ),Hiroshi Kimura(Hiroshi Kimura ),Toshihiko Kinoshita(Toshihiko Kinoshita ),Masaomi Iyo(Masaomi Iyo ),Yoshiteru Takekita(Yoshiteru Takekita ) 대한정신약물학회 2023 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.21 No.1
Dopamine supersensitivity psychosis (DSP) is an unstable clinical condition observed in individuals with schizophrenia who have been treated with an antipsychotic medication at a high dosage and/or for a long period. An up-regulation of dopamine D2 receptors (DRD2) is thought to be involved in the essential pathology of DSP. An antipsychotic agent with both tight binding to DRD2 and a long half-life is generally effective for treating DSP, but a patient who meets the criteria of treatment-resistant schizophrenia sometimes needs treatment with clozapine. We report the case details of two patients whose DSP was not controlled with several antipsychotics but was successfully controlled with asenapine. Asenapine binds to a broad range of dopamine receptors and serotonin receptors, and it is thus distinct from other atypical antipsychotics. The unique profile of asenapine may contribute to the control of severe DSP symptoms in individuals with schizophrenia.
Shigenori Tadokoro,Naho Nonomura,Nobuhisa Kanahara,갠지하시모토,Masaomi Iyo 대한정신약물학회 2017 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.15 No.1
Dopamine supersensitivity psychosis (DSP) is a type of acute exacerbation of recurrent psychosis caused by long-term treatment with antipsychotics in schizophrenic patients. Although DSP is exceedingly troublesome for clinicians, effective treatment has not yet been established. Based on clinical research and our animal study, we hypothesize that aripiprazole, an atypical antipsychotic, may reduce the exacerbation of recurrent psychotic episodes. We report the case of a 46-year-old female who suffered from schizophrenia with DSP. In this case, sustained treatment with a high dose of aripiprazole gradually reduced the severity of her recurrent psychotic episodes. In conclusion, sustained treatment with aripiprazole may reduce the exacerbation of recurrent psychotic episodes in schizophrenic patients with DSP, and may be an effective treatment of DSP.
Yuko Tanibuchi,Yuko Fujita,Mao Horio,Masaomi Iyo,갠지하시모토 대한정신약물학회 2010 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.8 No.3
Objective: Accumulating evidence suggests that α1-adrenoceptors are involved in the mechanisms of action of some antipsychotic drugs. The purpose of this study is to examine the effects of quetiapine, an atypical antipsychotic drug with antagonist activity at α1-adrenoceptors, on prepulse inhibition (PPI) deficits in mice after a single administration of the NMDA receptor antagonist dizocilpine. Methods: Effects of quetiapine on dizocilpine-induced PPI deficits in mice were examined. Furthermore, we examined the role of α1-adrenoceptors in the mechanisms of action of quetiapine. Results: Pretreatment with quetiapine (3, 10, or 30 mg/kg, p.o.) significantly attenuated dizocilpine (0.1 mg/kg, s.c.)-induced PPI deficits in mice in a dose-dependent manner. Furthermore, dizocilpine-induced PPI deficits were also significantly ameliorated by pretreatment with the selective α1-adrenoceptor antagonist prazosin (1.0 mg/kg, p.o.). Conclusion: These findings suggest that quetiapine ameliorates dizocilpine-induced PPI deficits in mice viaα1-adrenoceptor antagonism, and hence, α1-adrenoceptor antagonism may play a prominent role in quetiapine’s psychopharmacological effects.
Effects of Cilostazol on Cognitive Deficits in Mice after Repeated Administration of Phencyclidine
갠지하시모토,Yuko Fujita,Tamaki Ishima,Mao Horio,Hiroko Hagiwara,Yuko Tanibuchi,Masaomi Iyo 대한정신약물학회 2010 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.8 No.1
Objective : To examine the effects of cilostazol, a selective inhibitor of type III phosphodiesterase (PDE), on cognitive deficits in mice after repeated administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP). Methods:Saline (10 ml/kg/day) or PCP (10 mg/kg/day) were administered subcutaneously to mice for 10 days (once daily on days 1−5 and 8−12). Three days (day 15) after the final administration of saline or PCP, vehicle (0.5% carboxymethylcellulose)or cilostazol (0.3, 3, 10 or 30 mg/kg/day) were administered orally for 14 consecutive days (once daily on days 15−28). The novel object recognition test (NORT) was performed 24 hours (day 29) after the final administration. Results:In the NORT, PCP -induced cognitive deficits in mice were improved significantly by subsequent sub-chronic (14 days)administration of cilostazol (3, 10 or 30 mg/kg/day), but not by the lowest dose of cilostazol (0.3 mg/kg/day). Conclusion:This study suggests that cilostazol ameliorates PCP-induced cognitive deficits in mice. Therefore, it is likely that cilostazol has therapeutic potential for cognitive deficits in schizophrenia.
갠지하시모토,Yuko Fujita,Mao Horio,Hiroko Hagiwara,Yuko Tanibuchi,Masaomi Iyo 대한정신약물학회 2010 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.8 No.2
This study was undertaken to examine the effects of cilostazol, a selective inhibitor of type III phosphodiesterase (PDE), on hyperlocomotion and prepulse inhibition (PPI) deficits in mice after a single administration of the N-methyl-D-aspartate (NMDA)receptor antagonist dizocilpine. A single oral administration of cilostazol (0.1 and 0.3 mg/kg) significantly attenuated hyperlocomotion and PPI deficits in mice after the administration of dizocilpine (0.1 mg/kg, subcutaneously). This study suggests that cilostazol may have antipsychotic activity in animal models of schizophrenia. Therefore, cilostazol may be a potential therapeutic drug for schizophrenia, given that cilostazol has been safely used throughout the world.
An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
Akihiro Shiina,Nobuhisa Kanahara,Tsuyoshi Sasaki,Yasunori Oda,Tasuku Hashimoto,Tadashi Hasegawa,Taisuke Yoshida,Masaomi Iyo,갠지하시모토 대한정신약물학회 2015 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.13 No.1
Objective: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia. Methods: We recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8. Results: A total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants. Conclusion: This result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia.
Masatomo Ishikawa,Muneyuki Sakata,Jun Toyohara,Keiichi Oda,Kenji Ishii,Jin Wu,Taisuke Yoshida,Masaomi Iyo,Kiichi Ishiwata,갠지하시모토 대한정신약물학회 2011 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.9 No.3
Objective: Agonists of α7-nicotinic acetylcholine receptors (nAChRs) have been developed as potential therapeutic drugs for neuropsychiatric diseases such as schizophrenia and Alzheimer’s disease. Positron emission tomography (PET) is a noninvasive brain imaging technique to measure receptor occupancy in the living human brain. Although much effort has been expended to create specific PET radioligands for α7-nAChRs in the brain, only 4-[^(11)C]methylphenyl-1,4-diazabicyclo[3.2.2.]nonane-4-carboxylate ([^(11)C]CHIBA-1001) is currently available for clinical studies. In contrast, two 5-hydroxytryptamine-3 (5-HT_3)receptor antagonists, tropisetron and ondansetron, have been used to treat patients with chemotherapy-induced or postoperative nausea and vomiting. Furthermore, tropisetron, but not ondansetron, possesses high affinity for α7-nAChRs. In the present study, we evaluated the receptor occupancy in the human brain after a single oral administration of tropisetron and ondansetron using [^(11)C]CHIBA-1001 and PET. Methods: Two serial dynamic PET scans using [^(11)C]CHIBA-1001 in healthy non-smoking male subjects were performed before and after receiving an oral administration of these medications. Results: A single oral administration of tropisetron, but not ondansetron, decreased the total distribution volume of [^(11)C]CHIBA-1001 in the human brain. Conclusion: This study shows that tropisetron, but not ondansetron, could bind to α7-nAChRs in the human brain after a single oral administration. Therefore, [^(11)C]CHIBA-1001 may be a useful PET radioligand to measure the occupancy of α7-nAChRs in the human brain.